SEC Form 4 · accession 0001209191-18-035174
Audentes Therapeutics, Inc. · BOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Natalie C. Holles
Officer — President and COO
Period of report
Jun 1, 2018
Accepted (ET)
Jun 4, 2018 · 4:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628738
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 1, 2018 | M | 5,090 | $2.7649 | A | 25,090 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $2.7649 | Jun 1, 2018 | M | 5,090 | D | — | Nov 6, 2025 | Common Stock | 5,090 | 164,729 | D |
Explanation of responses
- F1Shares acquired in connection with the exercise of stock options described in Table II.
- F2The option vests as to 25% of the total shares on August 17, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on August 17, 2019, subject to the reporting person's provision of service to the issuer on each vesting date.